Escherichia coli Antimicrobial Susceptibility Reduction amongst HIV-Infected Individuals at the University Teaching Hospital, Lusaka, Zambia

Freeman Chabala 1,*, Mutinta Madubasi 2, Mable Mwale Mutengo 1, Njeleka Banda 3, Kaunda Yamba 3 and Patrick Kaonga 4,5

1 The Institute of Basic and Biomedical Sciences, Levy Mwanawasa Medical University, Lusaka 10101, Zambia; mmutengo@yahoo.com
2 Department of Applied Sciences, Lusaka Apex Medical University, Lusaka 10101, Zambia; tintamadubansi9@gmail.com
3 Department of Pathology and Microbiology, School of Medicine, University of Teaching Hospital, Lusaka 10101, Zambia; njeleka.banda@yahoo.co.uk (N.B.); kaundayamba@gmail.com (K.Y.)
4 Tropical Gastroenterology and Nutrition Group, University Teaching Hospital, Lusaka 10101, Zambia; patrickkaonga@gmail.com
5 Department of Internal Medicine, School of Medicine, University of Zambia, Lusaka 10101, Zambia

* Correspondence: wagadfreeman86@gmail.com; Tel.: +260-977142060

Received: 9 April 2020; Accepted: 4 May 2020; Published: 12 May 2020

Abstract: Increased antimicrobial resistance among Human Immunodeficiency Virus (HIV)-infected individuals to commonly used antibiotics in the treatment of gastroenteritis is a public health concern, especially in resource-limited settings. We set out to compare the antimicrobial susceptibility pattern of Escherichia coli (E. coli) isolates from HIV-infected and HIV-uninfected individuals at a tertiary hospital in Lusaka, Zambia. An analytical cross-sectional study was conducted at the University Teaching Hospital from May 2019 to August 2019. Stool samples were screened, and 79 HIV-infected individuals matched by age and sex with 84 HIV-uninfected individuals that presented with E. coli-associated gastroenteritis were studied. Demographics were collected from the Laboratory Information System (LIS) and stool samples were collected in a sterile leak-proof container. Samples were cultured and only those where E. coli was isolated were included in the study and tested for antimicrobial susceptibility by the Kirby–Bauer disk diffusion technique. HIV-positive individuals were 3 times (adjusted odds ratio (AOR) = 3.17; 95% CI (1.51, 6.66); p < 0.001) more likely to be resistant to quinolones compared with their HIV-negative counterparts. Similarly, HIV-positive individuals were almost 4 times (AOR = 3.97, 95% CI (1.37, 11.46); p = 0.011) more likely to have multidrug-resistant E. coli compared with those who were HIV-negative. HIV infection was associated with reduced E. coli susceptibility to commonly used antibiotics, and most cases showed resistance.

Keywords: Escherichia coli; antimicrobial susceptibility; Human Immunodeficiency Virus; bacterial gastroenteritis; Zambia

1. Introduction

Infection with the Human Immunodeficiency Virus (HIV) is a public health problem that is associated with immunosuppression and an augmented predisposition to opportunistic infections [1,2]. Escherichia coli (E. coli) is one of the most common etiological agents of bacterial gastroenteritis (GE) amongst HIV-infected individuals, whose disease presents with varying severity [3]. Approximately 50% of HIV-infected individuals succumb to bacterial GE, whose disease severity depends on many factors and has high attributable mortality, especially in resource-poor settings [4,5]. On one hand,
Highly Active Antiretroviral Therapy (HAART), a group of different classes of drugs that are used in the treatment of HIV [6], and prophylactic management of opportunistic infections have significantly improved clinical outcomes and overall survival of HIV-infected individuals; others have reported reduced diarrhoeal episodes in bacterial GE [7]. On the other hand, the treatment of diarrhoea in HIV-infected individuals remains a major challenge in this era of marked antimicrobial resistance [8,9]. This problem is ascribed to frequent visits to health facilities for medical check-ups and continuous exposure to antibiotic therapy and prophylaxis [9,10].

A Zambian study conducted during the pre-HAART era reported that Enterobacteriaceae including nontyphoidal Salmonellae, *Shigella flexneri*, and *Shigella dysenteriae* organisms had reduced antimicrobial susceptibility while *E. coli* did not [11], but studies elsewhere have shown increased antimicrobial resistance in *E. coli* [10,12]. However, after 17 years it was unclear whether the situation had changed or not; therefore, we set out to determine the antibiotic susceptibility pattern of *E. coli* isolated among HIV-infected individuals attending a tertiary hospital in Lusaka, Zambia. Findings would provide baseline data to inform a local antibiogram and provide updated specific antibiotics that are currently sensitive to *E. coli* among HIV-infected individuals.

2. Materials and Methods

2.1. Study Setting

This was a hospital-based analytical cross-sectional study conducted at the University Teaching Hospital (UTH), Lusaka, Zambia, from May 2019 to August 2019. The UTH is the largest referral hospital in Zambia [13]. About 68,000 individuals aged between 15 and 19 years are living with HIV and, according to the Zambia Population-Based HIV Impact Assessment (ZAMPHIA), the prevalence of the disease is 14.9% in this population [14].

2.2. Study Population

We screened and consecutively enrolled HIV-positive and HIV-negative individuals that presented with GE due to *E. coli*. We matched the cases to the controls by age and sex.

2.3. Sample Size Justification

Sample size calculation was done using the PS Power and Sample Size Calculations (Version 3.0 William D. Dupont and Walton D. Plummer). We designed an analytical cross-sectional study of HIV-positive (cases) and HIV-negative (controls) with one control per case. Prior research findings indicated that the prevalence of multidrug resistance amongst HIV-negative patients was 0.083 [15]. Assuming that the true prevalence rate of multidrug resistance in HIV-positive patients was 0.24, a sample size of 85 HIV-positive patients and 85 HIV-negative patients was required to reject the null hypothesis that these two proportions are equal with 0.8 power (Figure 1.) and 0.05 Type I error probability. We used an uncorrected chi-squared statistic to evaluate this null hypothesis using the formula below.

\[
2N = \frac{2\left(Z_{\alpha/2} \sqrt{2P(1-P)} + Z_{\beta} \sqrt{P_A(1-P_A) + P_B(1-P_B)}\right)^2}{(P_B - P_A)^2}
\]

\[
P = \frac{(P_A - P_B)^2}{2}
\]

\[
P_A = \text{proportion of multidrug resistance among HIV-negative patients}
\]

\[
P_B = \text{proportion of multidrug resistance among HIV-positive patients}
\]

We want to test \( H_0: P_A = P_B \) vs. \( H_1: P_A \neq P_B \) (\( P = \text{true value} \))

With significance level \( Z_{\alpha/2} \) and power \( 1 - \beta \) to detect a difference of \( \delta = P_A - P_B \)
were cultured on Xylose Lysine Deoxycholate (XLD) and MacConkey (MAC) and Xylose following enrichment on Selenite-F Broth (Thermo Scientific, Hampshire, United Kingdom). 

2.7. Antimicrobial Susceptibility Test

E. coli isolation and phenotypic characterization were conducted using the recommended culture method and all the biochemical tests were performed as described elsewhere [16]. Stool samples were cultured on Xylose Lysine Deoxycholate (XLD) and MacConkey (MAC) and Xylose following enrichment on Selenite-F Broth (Thermo Scientific, Hampshire, United Kingdom). E. coli was characterized using biochemical tests and serotyping was performed using commercial anti-sera (BD Diagnostics, Franklin Lakes, New Jersey, USA).

2.8. Data and Specimen Collection

Demographic characteristics such as age, sex, HIV status, and severity of diarrhea were obtained from the Laboratory Information System (LIS) model Build 981 (Disa*Lab, Cape Town, South Africa). A single stool specimen was obtained from each participant in a sterile leak-proof, disinfectant-free container and transported within 2 hours of collection to the laboratory for analysis and culture.

2.4. Sampling Strategy

We made an excel spreadsheet of HIV-positive and HIV-negative patients infected with E. coli in the period between January 2019 and March 2019. We had a total of 186 patients infected with E. coli but only 163 had known HIV status; 84 HIV-positive and 79 HIV-negative. We included all the participants in the study with known HIV status and excluded the 23 with unknown HIV status.
fluoroquinolones, which are amongst the main drugs of choice in the treatment of infection due to *E. coli* in this setting.

### 2.8. Statistical Analysis

Data were entered in Epi Data version 3.1 (Epi Data Corp., Odense, Denmark) and exported into Stata 15 (StataCorp., College Station, Texas, USA) for analysis. The bootstrap median and a 95% confidence interval were used to estimate the central tendency of continuous variables, such as age, while frequencies and percentages were used to summarize categorical variables. The Shapiro–Wilk test was used to test for normality for continuous variables. An unpaired T-test was used for comparing two normally distributed independent variables and the Wilcoxon–Mann–Whitney rank-sum test was used in cases where the dependent variable was not normally distributed. We used multiple logistic regression to estimate the odds of having resistance to aminoglycosides, resistance to quinolones, and resistance to both aminoglycosides and quinolones on condition for age, sex, HIV status, and severity of diarrhoea in the multiple regression models.

### 2.9. Ethical Approval

Permission to conduct the study was sought from the UTH management and ethical approval was obtained from ERES Converge (Ref no. 2018-Nov-042).

### 3. Results

There were 84 HIV-positive and 79 HIV-negative individuals. HIV-positive individuals were younger than HIV-negative individuals by a median age of 2 years $p < 0.001$: the median age of HIV-positive individuals was 13 years (bootstrap 95% CI (12.5, 13.5) vs. HIV-negative 16 years (bootstrap 95% CI (15.1, 16.9). In the HIV-positive group, 46 (54.7%) were females while in the HIV-negative group 41 (51.9%) were. The majority of individuals had acute diarrhoea in both groups: 38 (49.4%) and 49 (58.3%) among HIV-positive and HIV-negative individuals, respectively (Table 1).

| Characteristic                  | HIV-Positive | HIV-Negative | $p$-Value |
|--------------------------------|--------------|--------------|-----------|
| Age (years) *                  | 13 (12.5, 13.5) | 16 (15.1, 16.9) | <0.001    |
| Sex (%) **                     |               |              |           |
| Male                           | 38 (45.3)     | 38 (48.1)    | 0.714     |
| Female                         | 46 (54.7)     | 41 (51.9)    |           |
| Diarrhoea severity (%) **      |               |              |           |
| Acute diarrhoea                | 38 (49.4)     | 49 (58.3)    | 0.665     |
| Persistent                     | 18 (9.1)      | 16 (13.1)    |           |
| Chronic diarrhoea              | 21 (41.5)     | 24 (28.6)    |           |

HIV = Human Immunodeficiency Virus; * median (Bootstrap 95% confidence interval); ** chi-square test used. Acute diarrhoea (<1 week), Persistent (1–2 weeks), Chronic (>2 weeks) [20].

#### 3.1. Simple Logistic Regression Models

Upon the comparison of the antimicrobial susceptibility of *E. coli* between HIV-positive and HIV-negative individuals, findings demonstrated marked antimicrobial resistance among HIV-positive individuals following simple logistic regression analyses. *E. coli* isolates from HIV-positive individuals were 1.9 times more likely to be resistant to Amikacin compared with those from HIV-negative individuals (95% CI [1, 3.5], $p = 0.05$). Isolates from HIV-positive individuals were 2.6 times more likely to be resistant to Piperacillin/Tazobactam compared with those from HIV-negative individuals (95% CI [1.4, 5], $p = 0.003$). Isolates from HIV-positive individuals were 4.9 times more likely to be resistant to Cotrimoxazole compared with those from HIV-negative individuals (95% CI (2.2, 10.9), $p < 0.001$). Isolates from HIV-positive individuals were 1.8 times more likely to be resistant to...
Ciprofloxacin compared with those from HIV-negative individuals (95% CI [1, 3.4], \( p < 0.05 \)). Isolates from HIV-positive individuals were 2.5 times more likely to be resistant to Nalidixic acid compared with those from HIV-negative individuals (95% CI [1.3, 4.7], \( p = 0.005 \)). Finally, isolates from HIV-positive individuals were 2.5 times more likely to be resistant to Nalidixic acid compared with those from HIV-negative individuals (95% CI [1.3, 4.7], \( p = 0.005 \)). However, there was no difference in the susceptibility of \( E. \ coli \) isolates from HIV-positive and HIV-negative individuals to antibiotics such as Ampicillin, Tobramycin, and Ceftriaxone, \( p > 0.05 \) (Table 2).

| Drug                        | COR  | 95% CI   | \( p \)-Value |
|-----------------------------|------|----------|----------------|
| Amikacin                    |      |          |                |
| HIV-negative                | Ref. | 1, 3.5   | 0.05          |
| HIV-positive                | 1.9  |          |                |
| Ampicillin                  |      |          |                |
| HIV-negative                | Ref. | 0.6, 4.2 | 0.311         |
| HIV-positive                | 1.6  |          |                |
| Tobramycin                  |      |          |                |
| HIV-negative                | Ref. | 0.9, 3.6 | 0.100         |
| HIV-positive                | 1.8  |          |                |
| Piperacillin/Tazobactam     |      |          |                |
| HIV-negative                | Ref. | 1.4, 5   | 0.003         |
| HIV-positive                | 2.6  |          |                |
| Cotrimoxazole               |      |          |                |
| HIV-negative                | Ref. | 2.2, 10.9| <0.001        |
| HIV-positive                | 4.9  |          |                |
| Ciprofloxacin               |      |          |                |
| HIV-negative                | Ref. | 1, 3.4   | 0.050         |
| HIV-positive                | 1.8  |          |                |
| Nalidixic acid              |      |          |                |
| HIV-positive                | Ref. | 1.3, 4.7 | 0.005         |
| HIV-positive                | 2.5  |          |                |
| Ceftriaxone                 |      |          |                |
| HIV-negative                | Ref. | 0.6, 2.2 | 0.640         |
| HIV-positive                | 1.2  |          |                |

\( \text{COR} = \text{crude odds ratio}; \text{Ref.} = \text{reference category}; \text{CI} = \text{confidence interval.} \)

3.2. The Multiple Logistic Regression Model

Three multiple logistic regression analyses were done to determine the probability of having resistance to aminoglycosides (amikacin and tobramycin), resistance to quinolones (Nalidixic acid and ciprofloxacin), and resistance to both aminoglycosides and quinolones (multidrug resistance) upon conditioning for age, sex, and clinical diagnosis. Findings showed that there was no association between resistance to aminoglycosides and HIV status, \( p = 0.244 \). However, HIV-positive individuals were 3 times (adjusted odds ratio (AOR) = 3.17; 95% CI (1.51, 6.66); \( p < 0.001 \)) more likely to be resistant to quinolones compared with their HIV-negative counterparts. Similarly, HIV-positive individuals were almost 4 times (AOR = 3.97, 95% CI (1.37, 11.46); \( p = 0.011 \)) more likely to have multidrug-resistant \( E. \ coli \) compared with those who were HIV-negative (Table 3).
Table 3. Multiple Logistic Regression Models of resistance to the family of antimicrobials.

| Variable         | AOR  | p-Value | 95% CI  |
|------------------|------|---------|---------|
| **Aminoglycosides** |      |         |         |
| HIV Status       |      |         |         |
| Negative Ref.    |      |         |         |
| Positive         | 1.49 | 0.244   | 0.76, 2.92 |
| Sex              |      |         |         |
| Female Ref.      |      |         |         |
| Male             | 1.09 | 0.805   | 0.57, 2.08 |
| Age (years)      | 0.96 | 0.125   | 0.90, 1.01 |
| Diarrhoea        |      |         |         |
| Persistent Ref.  |      |         |         |
| Acute            | 1.74 | 0.198   | 0.75, 4.03 |
| Chronic          | 2.01 | 0.155   | 0.77, 5.25 |
| **Quinolones**   |      |         |         |
| HIV Status       |      |         |         |
| Negative Ref.    |      |         |         |
| Positive         | 3.17 | <0.001  | 1.51, 6.66 |
| Sex              |      |         |         |
| Female Ref.      |      |         |         |
| Male             | 1.36 | 0.406   | 0.66, 2.78 |
| Age (years)      | 1.01 | 0.827   | 0.95, 1.07 |
| Diarrhoea        |      |         |         |
| Persistent Ref.  |      |         |         |
| Acute            | 1.35 | 0.517   | 0.54, 3.39 |
| Chronic          | 1.16 | 0.771   | 0.42, 3.26 |
| **Multidrug-resistant** | | | |
| HIV Status       |      |         |         |
| Negative Ref.    |      |         |         |
| Positive         | 3.97 | 0.011   | 1.37, 11.46 |
| Sex              |      |         |         |
| Female Ref.      |      |         |         |
| Male             | 1.13 | 0.795   | 0.45, 2.86 |
| Age (years)      | 0.99 | 0.908   | 0.92, 1.08 |
| Diarrhoea        |      |         |         |
| Persistent Ref.  |      |         |         |
| Acute            | 1.26 | 0.703   | 0.38, 4.20 |
| Chronic          | 1.00 | 0.997   | 0.27, 3.79 |

AOR = adjusted odds ratio; Ref. = reference category; CI = confidence interval; HIV = Human Immunodeficiency Virus; Acute diarrhoea (<1 week), Persistent (1–2 weeks), Chronic (>2 weeks).

4. Discussion

*E. coli* is a common cause of bacterial GE worldwide and a major public health problem [1,21]. Amongst HIV-positive individuals, *E. coli* is one of the leading causes of morbidity and mortality, especially in developing countries where sanitation and access to clean and safe water is a challenge. Unfortunately, information about the susceptibility pattern of stool isolates of this organism to commonly used antibiotics in the HIV population is scarce [22]. Literature has demonstrated a decline in antimicrobial susceptibility of bacteria to commonly used antibiotics in HIV-positive compared with HIV-negative individuals, but little information exists to explain this finding and the magnitude of the problem [1,23,24].

In this study, we set out to determine an association between HIV infection and decline in susceptibility of *E. coli* to commonly used antibiotics in Zambia. In the study population, HIV-positive individuals were significantly younger than HIV-negative individuals with a median age of 13 years compared with HIV-negative individuals with one of 16 years. This age difference might concur with allegations that the majority of HIV adolescents could be infected by vertical transmission as most
adolescents become sexually active between 15 and 19 years of age. In Ethiopia, the median age for the sexual debut was 16.6 years [25]; in South Africa, it was 16 years for females and 15 years for males [26]; and in Malawi, it was 15 to 19 years [27]. Among the HIV-positive individuals, there was a female preponderance observed that could be due to greater biological susceptibility to HIV infection due to a larger mucous area being at risk of exposure to HIV during sexual intercourse [28] and vulnerabilities created by imbalanced social, cultural, and economic status, especially in developing countries [29].

Chronic diarrhoea was more prevalent among HIV-positive compared with HIV-negative individuals, concurring with reports elsewhere [30]. This finding is attributable to reduced immunity following depletion of Cluster of Differentiation (CD) 4 cells in HIV that permits diseases’ progression and vulnerability to chronicity [5,30]. Furthermore, there was a significant decline in zones of inhibition among antibiotics such as amikacin, ampicillin, tobramycin, piperacillin/tazobactam, ciprofloxacin, and nalidixic acid among HIV-positive compared with HIV-negative individuals. This finding is in conformity with reports from Cameroon that E. coli in HIV-positive individuals was mostly resistant to antibiotics compared with HIV-negative individuals [3,10,23]. It was suggested that the finding of resistance to common antibiotics in HIV-positive individuals was probably a result of frequent exposure to antibiotics on follow-ups and inappropriate use as well as misuse of antibiotics due to frequent illness [31,32]. However, the real underpinning mechanism of antimicrobial resistance in HIV could not quite be ascertained and remains contentious. It is an important puzzle to solve considering the lack of clarity as to whether this reduction is true for other bacteria and the magnitude of the problem.

Antimicrobial resistance is one of the global public health concerns and the advent of HIV is an aggravating factor. On one hand, our study showed that, regardless of HIV status, E. coli isolates were resistant to ampicillin and tobramycin, which are amongst the most frequently empirically prescribed antibiotics via self-medication; they are prescribed as prophylaxis after surgical procedures and resistance is due to inappropriate use and overseuse. It was noted that most of the antibiotics that showed sensitivity amongst HIV-negative individuals proved to be either resistant or intermediate resistant in HIV-positive individuals; this problem becomes more detrimental because currently there is no algorithm specifically for HIV-infected individuals and both the drugs of choice and doses remain the same, provided the aetiology remains the same. Our results from adjusted logistic regression indicated that HIV-positive individuals were more likely to be resistant to quinolones and experience multidrug resistance. There are possible implications for empirical treatment; since for some antibiotics there is no difference given the HIV status while for others HIV-positive individuals have higher rates of resistance, one could argue that there is a high proportion of HIV-positive individuals receiving treatment for bacterial GE due to E. coli that may not be benefitting much from the treatment. Instead, treatment is likely propagating antimicrobial resistance. Furthermore, this could give rise to the proliferation of multidrug-resistant E. coli variants that can multiply persistently with HIV-positive individuals being a reservoir for infection, thereby exacerbating the public health system distress. These results suggest the need for further investigation into antimicrobial resistance in HIV, for identifying the mechanistic processes underlying it, and quantifying the magnitude of the problem and effects on clinical and public health outcomes. This study may be an epiphany that sets a benchmark or gives preliminary information about prevailing issues in antimicrobial use amongst HIV-infected individuals in Zambia and possibly other developing countries. Ultimately, we highlight the importance of antimicrobial susceptibility testing for bacteria causing diarrhoea and other bacterial diseases among HIV-positive individuals and the danger of assuming the equal efficacy of antibiotics without considering HIV status. Finally, in order for the HIV population to circumvent negative consequences, the study suggests the need for constant monitoring of antibiotic susceptibility patterns in HIV-infected individuals and the possible need for the re-examination of the current antibiotic algorithm.

5. Limitations

Our study has several limitations. First, the study was conducted at one tertiary hospital in Lusaka, Zambia. We therefore advise that any attempts to generalize our findings should be cautious.
Second, as our study had an analytical cross-sectional design, no causal relationship could be deduced between HIV and antimicrobial resistance. Third, individuals who presented to the hospital with GE symptoms were seen by different clinicians on duty; this could have created bias on who was sent or not sent to the laboratory for a stool culture.

6. Conclusions

HIV infection is associated with the reduced susceptibility of faecal E. coli to many families of antibiotics and caution should be taken when treating these individuals as the drugs may not work effectively.

Author Contributions: F.C.: Conceptualization, methodology, software, validation, formal analysis, supervision, and original draft writing; P.K.: Verified analytical methods, formal analysis, methodology, supervision, software and overall responsibility of writing original manuscript; M.M., N.B., and K.Y.: Experiment, data curation, resources, and investigations; M.M.M., P.K., and F.C.: Manuscript writing, editing, visualization, supervision, and funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding: No external source of funding was obtained for this study.

Acknowledgments: Thanks are given to The Zambia Ministry of Health for permitting data usage, University Teaching Hospital management for permitting facility usage and access to laboratory services and data, members of staff at the University Teaching Hospital laboratory for supporting the data collection process and quality control, Lusaka Apex Medical University, the Southern African Consortium for Research Excellency, and Levy Mwanawasa Medical University for support and critique of the research.

Conflicts of Interest: The authors declare that no competing interests exist.

References
1. Evans, C.; Humphrey, J.H.; Ntozini, R.; Prendergast, A.J. HIV-Exposed uninfected infants in zimbabwe: Insights into health outcomes in the pre-antiretroviral therapy era. Front. Immunol. 2016, 7, 190. [CrossRef]
2. Furler, R.L.; Newcombe, K.L.; Del Rio Estrada, P.M.; Reyes-Terán, G.; Uittenbogaart, C.H.; Nixon, D.F. Histoarchitectural deterioration of lymphoid tissues in HIV-1 infection and in aging. AIDS Res. Hum. Retrovir. 2019, 35, 1148–1159. [CrossRef] [PubMed]
3. Kebede, A.; Aragie, S.; Shimelis, T. The common enteric bacterial pathogens and their antimicrobial susceptibility pattern among HIV-infected individuals attending the antiretroviral therapy clinic of Hawassa university hospital, southern Ethiopia. Antimicrob. Resist. Infect. Control 2017, 6, 128. [CrossRef] [PubMed]
4. Datta, D.; Gazzard, B.; Stebbing, J. The diagnostic yield of stool analysis in 525 HIV-1-infected individuals. AIDS 2003, 17, 1711–1713. [CrossRef] [PubMed]
5. Cárcamo, C.; Hooton, T.; Wener, M.H.; Weiss, N.S.; Gilman, R.; Arevalo, J.; Carrasco, J.; Seas, C.; Caballero, M.; Holmes, K.K. Etiologies and manifestations of persistent diarrhea in adults with HIV-1 infection: A case-control study in Lima, Peru. J. Infect. Dis. 2005, 191, 11–19. [CrossRef]
6. Lu, D.Y.; Wu, H.Y.; Yarla, N.S.; Xu, B.; Ding, J.; Lu, T.R. HAART in HIV/AIDS treatments: Future trends. Infect. Disord. Drug Targets 2018, 18, 15–22. [CrossRef]
7. Klatt, N.R.; Cheu, R.; Birse, K.; Zevin, A.S.; Perner, M.; Noël-Romas, L.; Grobler, A.; Westmacott, G.; Xie, I.Y.; Mansoor, L.; et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science 2017, 356, 938–945. [CrossRef]
8. Iyamba, J.-M.L.; Wambale, J.M.; Takaisi-Kikuni, N.Z.B. Antimicrobial susceptibility patterns of enterobacteriaceae isolated from HIV-infected patients in Kinshasa. Pan Afr. Med J. 2014, 17, 179. [CrossRef]
9. Marami, D.; Balakrishnan, S.; Seyoum, B. Prevalence, antimicrobial susceptibility pattern of bacterial isolates, and associated factors of urinary tract infections among HIV-Positive Patients at Hiwot Fana Specialized University Hospital, Eastern Ethiopia. Can. J. Infect. Dis. Med Microbiol. 2019, 2019, 8. [CrossRef]
10. Ngalani, O.J.; Mbaveng, A.T.; Marbou, W.J.; Ngai, R.Y.; Kuete, V. Antibiotic Resistance of Enteric Bacteria in HIV-Infected Patients at the Banka Ad-Lucem Hospital, West Region of Cameroon. Can. J. Infect. Dis. Med Microbiol. 2019, 2019, 9381836. [CrossRef]
11. Mwansa, J.; Mutela, K.; Zulu, I.; Amadi, B.; Kelly, P. Antimicrobial sensitivity in enterobacteria from AIDS patients, Zambia. Emerg. Infect. Dis. 2002, 8, 92–93. [CrossRef] [PubMed]

12. Marbou, W.J.T.; Kuete, V. Bacterial resistance and immunological profiles in HIV-infected and non-infected patients at Mbouda AD LUCEM Hospital in Cameroon. J. Infect. Public Health 2017, 10, 269–276. [CrossRef]

13. UNAIDS. Data from: AIDSinfo; UNADIS Joint United Nations Programme on HIV/AIDS: Geneva, Switzerland, 2016.

14. ZAMPHIA, Zambia Population-Based HIV Impact Assessment 2016; Ministry of Health: Lusaka, Zambia, 2016.

15. Reinheimer, C.; Keppler, O.T.; Stephan, C.; Wichelhaus, T.A.; Friedrichs, I.; Kempf, V.A. Elevated prevalence of multidrug-resistant gram-negative organisms in HIV positive men. BMC Infect. Dis. 2017, 17, 206. [CrossRef]

16. Baron, E.J. Classification. In Medical Microbiology; Baron, S., Ed.; The University of Texas Medical Branch at Galveston: Galveston, Texas, USA, 1996.

17. Reller, L.B.; Weinstein, M.; Jorgensen, J.H.; Ferraro, M.J. Antimicrobial susceptibility testing: A review of general principles and contemporary practices. Clin. Infect. Dis. 2009, 49, 1749–1755.

18. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Clinical Laboratory Standards Institute: Pennsylvania, USA, 2009.

19. Johnson, J.R.; Johnston, B.; Clabots, C.; Kuskowski, M.A.; Castanheira, M. Escherichia coli Sequence Type ST131 as the Major Cause of Serious Multidrug-Resistant, E. coli Infections in the United States. Clin. Infect. Dis. 2010, 51, 286–294. [CrossRef]

20. Trynaadh. Approach to Chronic Diarrhea. 2018. Available online: https://drtrinadh.wordpress.com/2018/07/13/the-journey-begins/ (accessed on 10 March 2020).

21. Okeke, I.N. Diarrheagenic Escherichia coli in sub-Saharan Africa: Status, uncertainties and necessities. J. Infect. Dev. Ctries 2009, 3, 817–842. [CrossRef]

22. Morpeth, S.C.; Thielman, N.M.; Ramadhani, H.O.; Hamilton, J.D.; Ostermann, J.; Kisenge, P.R.; Shao, H.J.; Reller, L.B.; Itamba, D.K.; Bartlett, J.A.; et al. Effect of trimethoprim-sulfamethoxazole prophylaxis on antimicrobial resistance of fecal Escherichia coli in HIV-infected patients in Tanzania. J. Acquir. Immune Defic. Syndr. 2008, 47, 585–591. [CrossRef] [PubMed]

23. Padmavathy, K.; Padma, K.; Rajasekaran, S. Multidrug Resistant CTX-M-Producing Escherichia coli: A Growing Threat among HIV Patients in India. J. Pathog. 2016, 2016, 6. [CrossRef]

24. Nga TV, T.; Parry, C.M.; Le, T.; Lan NP, H.; Diep, T.S.; Campbell, J.I.; Van Minh Hoang, N.; Dung, L.T.; Wain, J.; Farrar, J.J.; et al. The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: Bloodstream infection trends over 15 years in southern Vietnam. Trans. R. Soc. Trop. Med. Hyg. 2012, 106, 26–34.

25. Nigatu, D.T.; Seme, A.; Fituma, S.; Segni, M.T. Sexual initiation and associated factors among young women in West Shoa, Ambo Town, Ethiopia: A community-based cross-sectional study. BMC Womens Health 2018, 18, 76. [CrossRef]

26. Richter, L.; Mabaso, M.; Ramjith, J.; Norris, S.A. Early sexual debut: Voluntary or coerced? Evidence from longitudinal data in South Africa—The Birth to Twenty Plus study. S. Afr. Med. J. 2015, 105, 304–307. [CrossRef] [PubMed]

27. Ningpuyaneyh, W.C.; Susuman, A.S. Sexual activity of the youth population in malawi: The emerging health care scenario. J. Asian Afr. Stud. 2016, 51, 433–444. [CrossRef]

28. Duarte, M.T.C.; Parada, C.M.G.d.L.; Souza, L.d.R.d. Vulnerability of women living with HIV/aids. Rev. Lat. Am. Enferm. 2014, 22, 68–75. [CrossRef] [PubMed]

29. Sia, D.; Onadja, Y.; Hajizadeh, M.; Heymann, S.J.; Brewer, T.F.; Nandi, A. What explains gender inequalities in HIV/AIDS prevalence in sub-Saharan Africa? Evidence from the demographic and health surveys. BMC Public Health 2016, 16, 1136. [CrossRef]

30. Jha, A.K.; Uppal, B.; Chadha, S.; Bhalla, P.; Ghosh, R.; Aggarwal, P.; Dewan, R. Clinical and Microbiological Profile of HIV/AIDS Cases with Diarrhea in North India. J. Pathog. 2012, 2012, 971958. [CrossRef]
31. Walker, B.; McMichael, A. The T-cell response to HIV. *Cold Spring Harb. Perspect. Med.* 2012, 2, a007054. [CrossRef]

32. Dikman, A.E.; Schonfeld, E.; Srisarajivakul, N.C.; Poles, M.A. Human immunodeficiency virus-associated diarrhea: Still an issue in the era of antiretroviral therapy. *Dig. Dis. Sci.* 2015, 60, 2236–2245. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).